Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.63-67, 2005 |
||
Title: Imatinib mesylate in Philadelphia chromosome-positive, chronic- phase myeloid leukemia after failure of interferon alpha | ||
Author: E., TOTHOVA ; A., KAFKOVA ; M., FRICOVA ; B., BENOVA ; G., KIRSCHNEROVA ; A., TOTHOVA ; | ||
Abstract: Imatinib mesylate (STI 571; Glivec) is a potent and selective
tyrosine kinase inhibitor. The introduction of imatinib has
chanced the philosophy of mechanisms of cancer therapy and already
changed current management of patients with chronic myeloid
leukemia (CML).
A total of 49 patients with later chronic phase CML in whom
previous therapy with interferon alpha had failed were treated
with 400 mg of oral imatinib daily. Patients were evaluated for
hematologic and cytogenetic responses. Time to progression,
survival, and toxic effects were also evaluated.
Complete hematologic responses were reported for 48 of 49 patients
studied (98 percent). The median time to a complete hematologic
response was 1.2 month; 89% of patients who had a response did so
within 4 months. Imatinib induced major cytogenetic responses in
73%; 62% had a complete responses. After a median follow-up of 18
months, CML had not progressed to the accelerated or blast phases
in an estimated 98% of patients, and 100 percent of the patients
were alive. Grade 3 or 4 nonhematologic toxic effects were
manageable. No one of patients discontinued treatment due to of
drug-related adverse events, and no treatment-related deaths
occurred.
The results of current study indicate that imatinib has a
significant therapy benefit in CML patients in whom treatment with
IFN alpha had failed. Therefore, has favorably changed the
prognosis for patients with chronic myelogenous leukemia
|
||
Keywords: chronic myeloid leukemia, cytogenetic resporse, imatinib mesylate | ||
Year: 2005, Volume: 52, Issue: | Page From: 63, Page To: 67 | |
|
download file |
|